{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T10:39:56Z","timestamp":1794566396635,"version":"4.9.1"},"reference-count":15,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Medicine High Impact Case Reports"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:p>Breast cancer receptor status plays a critical role in treatment selection, yet receptor evolution throughout disease progression remains a significant challenge. This case describes a 58-year-old female initially diagnosed with estrogen receptor (ER)-positive (95%), progesterone receptor (PR)-negative (&lt;5%), human epidermal growth factor receptor 2 (HER2)-negative (immunohistochemistry [IHC] 0, fluorescence in situ hybridization-negative) invasive ductal carcinoma. Over 6\u2009years, her tumor transitioned to triple-negative breast cancer at recurrence, then reacquired ER expression (80%) in metastatic mediastinal lymph nodes. HER2 status evolved from IHC 0\u2009\u2192\u2009HER2-low (IHC 1+\u2009\u2192\u2009IHC 2+), directly influencing therapy selection. These receptor changes led to major systemic treatment modifications, including endocrine therapy, immunotherapy, CDK4\/6 inhibitors, and antibody\u2013drug conjugates. Given the extended response duration and improved tolerability of targeted therapies, accurate receptor assessment is essential to ensure that patients receive the most effective treatment. Literature reports receptor discordance rates of ER loss (19%), PR loss (34%), and HER2 fluctuations (15%), reinforcing the necessity of biopsy-driven treatment adaptation. While serial biopsies remain invasive, they provide essential molecular insights that optimize systemic therapy choices, allowing patients to remain on the most appropriate, well-tolerated regimen for as long as possible. This case highlights the clinical significance of receptor evolution and advocates for biopsy-guided precision oncology in metastatic breast cancer management. Ensuring accurate receptor reassessment through periodic molecular profiling can maximize therapeutic efficacy, improving response rates, treatment tolerability, and overall patient outcomes.<\/jats:p>","DOI":"10.1177\/23247096251362974","type":"journal-article","created":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T09:56:11Z","timestamp":1753782971000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Dynamic Changes in Breast Cancer Receptor Status: A Case Report Highlighting the Importance of Repeat Biopsies in Guiding Treatment Strategies"],"prefix":"10.1177","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1115-2029","authenticated-orcid":false,"given":"Navkirat","family":"Kahlon","sequence":"first","affiliation":[{"name":"Mass General Cancer Center at Wentworth-Douglass Hospital, Dover, NH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2395-6315","authenticated-orcid":false,"given":"Sujatha","family":"Baddam","sequence":"additional","affiliation":[{"name":"Internal Medicine, Huntsville Hospital, AL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahush","family":"Bansal","sequence":"additional","affiliation":[{"name":"Internal Medicine,University of Toledo Medical Center, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaheer","family":"Qureshi","sequence":"additional","affiliation":[{"name":"The Frank H. Netter M.D. School of Medicine, Quinnipiac University, Bridgeport, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jhansi","family":"Maradana","sequence":"additional","affiliation":[{"name":"Mass General Cancer Center at Wentworth-Douglass Hospital, Dover, NH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,7,29]]},"reference":[{"key":"e_1_3_3_2_2","first-page":"1030","article-title":"HER2-targeted therapies in breast cancer: current perspectives","volume":"21","author":"Swain SM","year":"2020","unstructured":"Swain SM, Baselga J, Hortobagyi GN, et al. HER2-targeted therapies in breast cancer: current perspectives. Lancet Oncol. 2020;21:1030-1045.","journal-title":"Lancet Oncol"},{"key":"e_1_3_3_3_2","first-page":"1258","article-title":"CDK4\/6 inhibitors in ER-positive breast cancer: expanding therapeutic strategies","volume":"39","author":"Turner NC","year":"2021","unstructured":"Turner NC, Ro J, Johnson K, et al. CDK4\/6 inhibitors in ER-positive breast cancer: expanding therapeutic strategies. J Clin Oncol. 2021;39:1258-1272.","journal-title":"J Clin Oncol"},{"key":"e_1_3_3_4_2","first-page":"545","article-title":"Checkpoint inhibitors in triple-negative breast cancer: clinical implications","volume":"16","author":"Schmid P","year":"2019","unstructured":"Schmid P, Adams S, Rugo HS, et al. Checkpoint inhibitors in triple-negative breast cancer: clinical implications. Nat Rev Clin Oncol. 2019;16:545-561.","journal-title":"Nat Rev Clin Oncol"},{"key":"e_1_3_3_5_2","first-page":"449","article-title":"PD-L1 expression and immunotherapy response in breast cancer","volume":"7","author":"Nanda R","year":"2021","unstructured":"Nanda R, Chow L, Smith DF, et al. PD-L1 expression and immunotherapy response in breast cancer. JAMA Oncol. 2021;7:449-458.","journal-title":"JAMA Oncol"},{"key":"e_1_3_3_6_2","first-page":"625","article-title":"Targeted therapies for HER2-low breast cancer: a paradigm shift","volume":"23","author":"Bardia A","year":"2022","unstructured":"Bardia A, Tolaney SM, Loirat D, et al. Targeted therapies for HER2-low breast cancer: a paradigm shift. Lancet Oncol. 2022;23:625-638.","journal-title":"Lancet Oncol"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-018-1050-7"},{"key":"e_1_3_3_8_2","first-page":"78","article-title":"Meta-analysis of receptor discordance in breast cancer and its prognostic implications","volume":"25","author":"Burzykowski T","year":"2023","unstructured":"Burzykowski T, Buyse M, Piccart-Gebhart MJ, et al. Meta-analysis of receptor discordance in breast cancer and its prognostic implications. Breast Cancer Res. 2023;25:78-89.","journal-title":"Breast Cancer Res"},{"key":"e_1_3_3_9_2","first-page":"928","article-title":"ER loss in metastatic breast cancer and its impact on survival outcomes","volume":"28","author":"Lindstr\u00f6m LS","year":"2019","unstructured":"Lindstr\u00f6m LS, Karlsson E, Bergh J, et al. ER loss in metastatic breast cancer and its impact on survival outcomes. Cancer Epidemiol Biomarkers Prev. 2019;28:928-935.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"e_1_3_3_10_2","first-page":"472","article-title":"Molecular evolution of breast cancer receptor status and its therapeutic implications","volume":"33","author":"Gong Y","year":"2022","unstructured":"Gong Y, Liu YR, Ma F, et al. Molecular evolution of breast cancer receptor status and its therapeutic implications. Ann Oncol. 2022;33:472-481.","journal-title":"Ann Oncol"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-022-03679-y"},{"key":"e_1_3_3_12_2","first-page":"1345","article-title":"ER, PR, and HER2 discordance in metastatic breast cancer: clinical implications","volume":"33","author":"Chen Y","year":"2020","unstructured":"Chen Y, Li J, Wang H, et al. ER, PR, and HER2 discordance in metastatic breast cancer: clinical implications. Mod Pathol. 2020;33:1345-1355.","journal-title":"Mod Pathol"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2645"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.45269"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1916623"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-025-22855-5"}],"container-title":["Journal of Investigative Medicine High Impact Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/23247096251362974","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/23247096251362974","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/23247096251362974","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:04:37Z","timestamp":1777449877000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/23247096251362974"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":15,"alternative-id":["10.1177\/23247096251362974"],"URL":"https:\/\/doi.org\/10.1177\/23247096251362974","relation":{},"ISSN":["2324-7096","2324-7096"],"issn-type":[{"value":"2324-7096","type":"print"},{"value":"2324-7096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]},"article-number":"23247096251362974"}}